Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

MODEL MEDICINES — Lobbying — Receipts Report

LD-2 disclosure · 3rd Quarter - Report

MODEL MEDICINES

via RESOLUTE-DC

3rd Quarter (July 1 - Sep 30) · 2024Posted Oct 14, 2024Filing document ↗LDA record ↗

Coverage · No income or expenses were reported on this filing.

Client

Name: MODEL MEDICINES
Description: US-based, artificial intelligence-driven drug discovery and development company
Location: California · United States of America

Registrant

Firm: RESOLUTE-DC
Location: Chicago, Illinois, United States of America

Lobbying activities

2 issues

Medical/Disease Research/Clinical Labs
Introduce Model Medicines and how the company is innovating at the intersection of data science, biology and drug development.
LobbyistsGREG GOLDNER
TargetedHealth & Human Services, Dept of (HHS)
Pharmacy
Introduce Model Medicines and how the company is innovating at the intersection of data science, biology and drug development.
LobbyistsGREG GOLDNER
TargetedHealth & Human Services, Dept of (HHS)

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.